Skin tests in the diagnosis of drug hypersensitivity reactions

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2778-2791

  Brockow, Knut ^a   Romano, Antonino ^b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Allergy Unit   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Allergy diagnosis; Drugs; Hypersensitivity; Intradermal tests; Patch tests; Prick tests; Skin tests

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CEPHALOSPORIN; CHYMOPAPAIN; CLINDAMYCIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; GENTAMICIN; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN E; INSULIN DERIVATIVE; IODINATED CONTRAST MEDIUM; MACROLIDE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PLATINUM COMPLEX; PYRAZOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOKINASE; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; TETRAZEPAM; UNINDEXED DRUG; VANCOMYCIN;

ALLERGIC URTICARIA; CELL MEDIATED CYTOTOXICITY; CLINICAL EVALUATION; CLINICAL FEATURE; DELAYED HYPERSENSITIVITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ERYTHEMA; HEART INFARCTION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INSULIN ALLERGY; INTRACUTANEOUS TEST; LABORATORY TEST; MACULOPAPULAR RASH; PATCH TEST; PENICILLIN ALLERGY; PRICK TEST; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SKIN ALLERGY; SKIN DISEASE; SKIN MANIFESTATION; SKIN TEST; STANDARDIZATION;

ANIMALS; DRUG HYPERSENSITIVITY; HUMANS; PHARMACEUTICAL PREPARATIONS; SKIN TESTS;

EID: 65949104831     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369821     Document Type: Review

References (124)

1. Ring J, Brockow K. Adverse drug reactions: Mechanisms and assessment. Eur Surg Res 2002; 34: 170-5.
2. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
3. Torres MJ, Blanca M, Fernandez J, Romano A, de Weck A, Aberer W, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58: 961-72.
4. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, et al. Diagnosis of nonimmediate reactions to β-lactam antibiotics. Allergy 2004; 59: 1153-60.
5. Brockow K, Christiansen C, Kanny G, Clement O, Barbaud A, Bircher A, et al. Management of hypersensivity reactions to iodinated contrast media. Allergy 2005; 60: 150-8.
6. Mertes PM, Laxenaire MC, Lienhart A, Aberer W, Ring J, Pichler WJ, et al. Reducing the risk of anaphylaxis during anaesthesia: Guidelines for clinical practice. J Investig Allergol Clin Immunol 2005; 15: 91-101.
7. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278: 1895-906.
8. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
9. Solensky R. Drug hypersensitivity. Med Clin North Am 2006; 90: 233-60.
10. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
11. Calkin JM, Maibach HI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993; 29: 223-33.
12. Bruynzeel DP, Maibach HI. Patch testing in systemic drug eruptions. Clin Dermatol 1997; 15: 479-84.
13. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139: 49-58.
14. Romano A, Torres MJ, Quaratino D, Di Fonso M, Perrone MR, Viola M, et al. Diagnostic evaluations of delayed hypersensitivity to systemically administered drugs. Allergy 1999; 54 (Suppl 58): 23-7.
15. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321-8.
16. Romano A, Viola M, Gaeta F, Rumi G, Maggioletti M. Patch testing in non-immediate drug eruptions. Allergy Asthma Clin Immunol 2008; 4: 66-74.
17. Schnyder B, Helbling A, Kappeler A, Pichler WJ. Drug-induced papulovesicular exanthema. Allergy 1998; 53: 817-8.
18. Torres MJ, Romano A, Mayorga C, Moya MC, Guzman AE, Reche M, et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: The role of skin testing. Allergy 2001; 56: 850-6.
19. Machet L, Vaillant L, Dardaine V, Lorette G. Patch testing with clobazam: Relapse of generalized drug eruption. Contact Dermatitis 1992; 26: 347-8.
20. Sachs B, Fischer-Barth W, Erdmann S, Merk HF, Seebeck J. Anaphylaxis and toxic epidermal necrolysis or Stevens-Johnson syndrome after nonmucosal topical drug application: Fact or fiction? Allergy 2007; 62: 877-83
21. Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol 2007; 7: 299-303.
22. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79: 660-77.
23. Scherer K, Grize L, Schindler C, Surber C, Bircher AJ. Reaction pattern to histamine and codeine in a human intradermal skin test model. Clin Exp Allergy 2007; 37: 39-46.
24. Bruynzeel DP, Ferguson J, Andersen K, Gonçalo M, English G, Goossen A, et al. Photopatch testing: A consensus methodology for Europe. J Eur Acad Dermatol Venereol 2004; 18: 679-82.
25. Wahlberg JE. Patch testing. In: Rycroft RJG, Menne T, Frosch PJ Eds, Textbook of contact dermatitis, 2nd ed. Berlin, Springer. 1995; 241-68.
26. Demoly P, Michel FB, Bousquet J. In vivo methods for study of allergy: Skin tests, techniques, and interpretation. In: Middleton E, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW Eds, Allergy, Principles and Practice, 5th ed. New York, Mosby Co. 1998; 430-9.
27. Romano A, Quaratino D, Di Fonso M, Papa G, Venuti A, Gasbarrini G. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol 1999; 103: 1186-90.
28. Romano A, Viola M, Mondino C, Pettinato R, Di Fonso M, Papa G, et al. Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int Arch Allergy Immunol 2002; 129: 169-74.
29. Executive summary of disease management of drug hypersensitivity: A practice parameter. Joint task force on practice parameters, the American academy of allergy, asthma and immunology, and the joint council of allergy, asthma and immunology. Ann Allergy Asthma Immunol 1999; 83: 665-700.
30. Romano A, Guéant-Rodriguez RM, Viola M, Amoghly F, Gaeta F, Guéant, JL. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy 2005; 35: 1234-42.
31. Torres MJ, Sánchez-Sabaté E, Alvarez J, Mayorga C, Fernández J, Padial A, et al. Skin test evaluation in nonimmediate allergic reactions to penicillins. Allergy 2004; 59: 219-24.
32. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112: 629-30.
33. de Groot AC. Patch testing - test concentrations and vehicles for 3700 chemicals. Amsterdam, Elsevier 1994.
34. Brockow K, Romano A, Aberer W, Bircher A, Barbaud A, Bonadonna P, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2008; in press.
35. Przybilla B, Aberer W, Bircher AJ, Brehler R, Brockow K, Dickel H, et al. Allergological approach to drug hypersensitivity reactions. J Dtsch Dermatol Ges 2008; 6: 240-3.
36. Hertl M, Jugert F, Merk HF. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995; 132: 215-20.
37. Britschgi M, von Greyerz S, Burkhart C, Pichler WJ. Molecular aspects of drug recognition by specific T cells. Curr Drug Targets 2003; 4: 1-11
38. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernández J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 2003; 58: 854-63.
39. Salkind AR, Cuddy PG, Foxworth JW. Is the patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 2001; 285: 2498-505.
40. Blanca M, Vega JM, Garcia J, Carmona MJ, Terados S, Avila MJ, et al. Allergy to penicillin with good tolerance to other penicillins; study of the incidence in subjects allergic to betalactams. Clin Exp Allergy 1990; 20: 475-81.
41. Macy E. Penicillin skin testing in pregnant women with a history of penicillin allergy and group B streptococcus colonization. Ann Allergy Asthma Immunol 2006; 97: 164-8.
42. Wong BB, Keith PK, Waserman S. Clinical history as a predictor of penicillin skin test outcome. Ann Allergy Asthma Immunol 2006; 97: 169-74.
43. Jost BC, Wedner HJ, Bloomberg GR. Elective penicillin skin testing in a pediatric outpatient setting. Ann Allergy Asthma Immunol 2006; 97: 807-12.
44. Bousquet PJ, Co-Minh HB, Arnoux B, Daures JP, Demoly P. Importance of mixture of minor determinants and benzylpenicilloyl poly-L-lysine skin testing in the diagnosis of β-lactam allergy. J Allergy Clin Immunol 2005; 115: 1314-6.
45. Matheu V, Perez-Rodriguez E, Sanchez-Machin I, de la Torre F, García-Robaina JL. Major and minor determinants are high-performance skin tests in β-lactam allergy diagnosis. J Allergy Clin Immunol 2005; 116: 1167-1168; author reply 1168-9.
46. Torres MJ, Blanca M; European Network for Drug Allergy (ENDA); EAACI Interest Group on Drug Hypersensitivity. Importance of skin testing with major and minor determinants of benzylpenicillin in the diagnosis of allergy to betalactams. Statement from the European Network for Drug Allergy concerning AllergoPen withdrawal. Allergy 2006; 61: 910-1.
47. Rodríguez-Bada JL, Montañez MI, Torres MJ, Mayorga C, Canto G, Perez-Inestrosa E, et al. Skin testing for immediate hypersensitivity to betalactams: Comparison between two commercial kits. Allergy 2006; 61: 947-51.
48. Romano A, Viola M, Bousquet PJ, Gaeta F, Valluzzi R, Caruso C, et al. A comparison of the performance of two penicillin reagent kits in the diagnosis of beta-lactam hypersensitivity. Allergy 2007; 62: 53-8
49. Blanca M, Mayorga C, Torres MJ, Warrington R, Romano A, Demoly P, et al. Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy 2002; 32: 192-7.
50. Blanca M, Romano A, Torres MJ, Demoly P, de Weck A. Continued need of appropriate betalactam-derived skin test reagents for the management of allergy to betalactams. Clin Exp Allergy 2007; 37: 166-73.
51. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sánchez F, et al. Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Allergy Clin Immunol 2000; 106: 1177-83.
52. Antunez C, Blanca-Lopez N, Torres MJ, Mayorga C, Perez-Inestrosa E, Montañez I, et al. Immediate allergic reactions to cephalosporins: Evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006; 117: 404-10.
53. Guéant JL, Guéant-Rodríguez RM, Viola M, Valluzzi RL, Romano A. IgE-mediated hypersensitivity to cephalosporins. Curr Pharm Des 2006; 12: 3335-45.
54. Romano A, Guéant-Rodriguez RM, Viola M, Pettinato R, Guéant JL. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004; 141: 16-22.
55. Romano A, Viola M, Guéant-Rodriguez RM, Gaeta F, Pettinato R, Guéant JL. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 2006; 354: 2835-7.
56. Romano A, Viola M, Guéant-Rodriguez RM, Gaeta F, Valluzzi R, Guéant JL. Brief communication: Tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med 2007; 146: 266-9.
57. Atanasković-Marković M, Gaeta F, Medjo B, Viola M, Nestorović B, Romano A. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy 2008; 63: 237-40.
58. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152: 968-74.
59. Romano A, Gaeta F, Valluzzi RL, Alonzi C, Viola M, Bousquet JP. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics; in press.
60. Birnbaum J, Vervloet D. Allergy to muscle relaxants. Clin Rev Allergy 1991; 9: 281-93.
61. Mertes PM, Laxenaire MC. Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol 2002; 19: 240-62.
62. Mertes PM, Moneret-Vautrin DA, Leynadier F, Laxenaire MC. Skin reactions to intradermal neuromuscular blocking agent injections: A randomized multicenter trial in healthy volunteers. Anesthesiology 2007; 107: 245-52.
63. Guéant-Rodríguez RM, Romano A, Barbaud A, Brockow K, Guéant JL. Hypersensitivity reactions to iodinated contrast media. Curr Pharm Des 2006; 12: 3359-372.
64. Kvedariene V, Martins P, Rouanet L, Demoly P. Diagnosis of iodinated contrast media hypersensitivity: Results of a 6-year period. Clin Exp Allergy 2006; 36: 1072-7.
65. Vernassiere C, Trechot P, Commun N, Schmutz JL, Barbaud A. Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis 2004; 50: 359-66.
66. Bircher AJ, Fluckiger R, Buchner SA. Eczematous infiltrated plaques to subcutaneous heparin: A type IV allergic reaction. Br J Dermatol 1990; 123: 507-14.
67. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: Diagnosis and management options. Allergy 2006; 61: 1432-40.
68. Hancock BW, Naysmith A. Hypersensitivity to chlorocresol-preserved heparin. Br Med J 1975; 3: 746-7.
69. Bircher AJ, Itin PH, Tsakiris DA, Surber C. Delayed hypersensitivity to one low-molecular-weight heparin with tolerance of other low-molecular-weight heparins. Br J Dermatol 1995; 132: 461-3.
70. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: An update. Blood Coagul Fibrinolysis 2006; 17: 605-13.
71. Earl HS, Sullivan TJ. Acute desensitization of a patient with cystic fibrosis allergic to both beta-lactam and aminoglycoside antibiotics. J Allergy Clin Immunol 1987; 79: 477-83.
72. Abeck D, Kuwert C, Segnini-Torres M, Przybilla B, Ring J. Streptomycin-induced anaphylactic reaction during in vitro fertilization (IVF). Allergy 1994; 49: 388-9.
73. Dyck ED, Vadas P. Anaphylaxis to topical bacitracin. Allergy 1997; 52: 870-1.
74. Iikura M, Yamaguchi M, Hirai K, Suenaga A, Fujiwara T, Fujii T, et al. Case report: Streptomycin-induced anaphylactic shock during oocyte retrieval procedures for in vitro fertilization. J Allergy Clin Immunol 2002; 109: 571-2.
75. Romano A, Viola M, Di Fonso M, Perrone MR, Gaeta F, Andriolo M. Anaphylaxis to steptomycin. Allergy 2002; 57: 1087-8.
76. Lee YD, Cho Y, Han MS. Anaphylaxis to ribostamycin. Allergy 2004; 59: 1134-5.
77. Viola M, Quaratino D, Gaeta F, Valluzzi RL, Caruso C, Rumi G, et al. Allergic reactions to antibiotics, mainly betalactams: Facts and controversies. Eur Ann Allergy Clin Immunol 2005; 37: 223-9.
78. Buergin S, Scherer K, Häusermann P, Bircher AJ. Immediate hypersensitivity to rifampicin in 3 patients: Diagnostic procedures and induction of clinical tolerance. Int Arch Allergy Immunol 2006; 140: 20-6.
79. Anne' S, Middleton E Jr, Reisman RE. Vancomycin anaphylaxis and successful desensitization. Ann Allergy 1994; 73: 402-4.
80. Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol 1991; 88:784-92.
81. Shapiro LE, Knowles SR, Weber E, Neuman MG, Shear NH. Safety of celecoxib in individuals allergic to sulfonamide: A pilot study. Drug Saf 2000; 26: 187-95.
82. Alonso MD, Marcos C, Davila I, de la Hoz B, Martin JA, Parra F, et al. Hypersensitivity to trimethoprim. Allergy 1992; 47: 340-2.
83. Asero R. Teicoplanin-induced anaphylaxis. Allergy 2006; 61: 1370.
84. Campi P, Pichler WJ. Quinolone hypersensitivity. Curr Opin Allergy Clin Immunol 2003; 3: 275-81.
85. Benahmed S, Scaramuzza C, Messaad D, Sahla H, Demoly P. The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial. Allergy 2004; 59: 1130-3.
86. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones. Clin Exp Allergy 2006; 36: 59-69.
87. Trautmann A, Bröcker EB, Klein CE. Hautreaktionen bei antituberkulöser Chemotherapie. Allergologie 1995; 18: 138-44.
88. Michel M, Dompmartin A, Szczurko C, Castel B, Moreau A, Leroy D. Eczematous-like drug eruption induced by synergistins. Contact Dermatitis 1996; 34: 86-7.
89. Alanko K. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis 1994; 31: 25-7.
90. Lee AY. Topical provocation in 31 cases of fixed drug eruption: Change of causative drugs in 10 years. Contact Dermatitis 1998; 38: 258-60
91. Kowalski ML, Woszczek G, Bienkiewicz B, Mis M. Association of pyrazolones drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy 1998; 28: 1153-8.
92. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, et al. Ig E-mediated immediate-type hypersensitivity to pyrazolones drug propyphenazone. J Allergy Clin Immunol 2003; 111: 882-8.
93. Macías E, Ruiz A, Moreno E, Laffond E, Dávila I, Lorente F. Usefulness of intradermal test and patch test in the diagnosis of non-immediate reactions to metamizol. Allergy 2007; 62: 1462-4.
94. Ordoqui E, De Barrio M, Rodriguez VM, Herrero T, Gil PJ, Baeza ML. Cross-sensitivity among oxicams in piroxicam-caused fixed drug eruption: two case reports. Allergy 1995; 50: 741-4.
95. Romano A, Pietrantonio F, Di Fonso M, Garcovich A, Chiarelli C, Venuti A, et al. Positivity of patch tests in cutaneous reaction to diclofenac. Two case reports. Allergy 1994; 49: 57-9.
96. Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salts hypersensitivity. J Allergy Clin Immunol 2007; 119: 726-30.
97. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; in press.
98. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19: 3126-9.
99. Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70: 201-6.
100. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001; 24: 767-79.
101. Wessbecher R, Kiehn M, Stoffel E, Moll I. Management of insulin allergy. Allergy 2001; 56: 919-20.
102. Baur X, Bossert J, Koops F. IgE-mediated allergy to recombinant human insulin in a diabetic. Allergy 2003; 58: 676-8.
103. Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol 1994; 93: 117-25.
104. Puig L, Nadal C, Fernandez-Figueras MT, Alomar A. Carbamazepine-induced drug rashes: Diagnostic value of patch tests depends on clinico-pathologic presentation. Contact Dermatitis 1996; 34: 435-7
105. Romano A, Pettinato R, Andriolo M, Viola M, Guéant-Rodríguez RM, Valluzzi RL, et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006; 12: 3373-81
106. Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis 2003; 48: 137-9.
107. Vaillant L, Camenen I, Lorette G. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol 1989; 125: 299.
108. Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 1990; 17: 235-9.
109. Bircher AJ, Levy F, Langauer S, Lepoittevin JP. Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. Acta Derm Venereol 1995; 75: 490-3.
110. Bircher AJ, Pelloni F, Langauer Messmer S, Muller D. Delayed hypersensitivity reactions to corticosteroids applied to mucous membranes. Br J Dermatol 1996; 135: 310-3.
111. Bircher AJ, Bigliardi P, Zaugg T, Makinen-Kiljunen S. Delayed generalized allergic reactions to corticosteroids. Dermatology 2000; 200: 349-51.
112. Vidal C, Tomé S, Fernandex-Redondo V, Tato F. Systemic allergic reaction to corticosteroids. Contact Dermatitis 1994; 31: 273-4.
113. Dooms-Goossens A, Morren M. Results of routine patch tests with corticosteroid series in 2073 patients. Contact Dermatitis 1992; 26: 182-91.
114. Padial A, Posadas S, Alvarez J, Torres MJ, Alvarez JA, Mayorga C, et al. Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism. Allergy 2005; 60: 665-70.
115. Felix RH, Comaish JS. The value of patch and other skin tests in drug eruptions. Lancet 1974; 1: 1017-9.
116. Ortega NR, Barranco P, López Serrano C, Romualdo L, Mora C. Delayed cell-mediated hypersensitivity to tetrazepam. Contact Dermatitis 1996; 34: 139.
117. Rochina A, Burchés E, Morales C, BrasóJV, Pelaéz A. Adverse reaction to pseudoephedrine. J Investig Allergol Clin Immunol 1995; 5: 235-6.
118. Romano A, Pietrantonio F, Garcovich A, Venuti A, Barone C. Delayed hypersensitivity to diltiazem in two patients. Ann Allergy 1992; 69: 31-2.
119. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19: 979-81.
120. Dykewicz MS, McGrath KG, Davison R, Kaplan KJ, Patterson R. Identification of patients at risk for anaphylaxis due to streptokinase. Arch Intern Med 1986; 146: 305-7.
121. Grammer LC, Schafer M, Bernstein D, Bernstein IL, Cogen F, Dolovich J, et al. Prevention of chymopapain anaphylaxis by screening chemonucleolysis candidates with cutaneous chymopapain testing. Clin Orthop Relat Res 1988; 234: 12-5.
122. Dogne JM, Thiry A, Supuran CT. Carbonic anhydrase inhibition: Insight into non-COX-2 pharmacological effect of some coxibs. Curr Pharm Des 2008; 14(7): 679-84.
123. Lau WM, White AW, Gallagher SJ, Donaldson M, McNaughton G, Heard CM. Scope and limitations of the co-drug approach to topical drug delivery. Curr Pharm Des 2008; 14(8): 794-802.
124. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008; 14(10): 953-61